Annual CFF
$388.14 M
-$113.07 M-22.56%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual cash flow from financing activities is $388.14 million, with the most recent change of -$113.07 million (-22.56%) on December 31, 2023.
- During the last 3 years, RARE annual CFF has fallen by -$212.13 million (-35.34%).
- RARE annual CFF is now -42.86% below its all-time high of $679.31 million, reached on December 31, 2019.
Performance
RARE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$11.17 M
-$373.76 M-97.10%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly cash flow from financing activities is $11.17 million, with the most recent change of -$373.76 million (-97.10%) on September 30, 2024.
- Over the past year, RARE quarterly CFF has dropped by -$14.06 million (-55.72%).
- RARE quarterly CFF is now -97.73% below its all-time high of $491.88 million, reached on September 30, 2022.
Performance
RARE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$726.66 M
-$14.06 M-1.90%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM cash flow from financing activities is $726.66 million, with the most recent change of -$14.06 million (-1.90%) on September 30, 2024.
- Over the past year, RARE TTM CFF has increased by +$667.25 million (+1123.05%).
- RARE TTM CFF is now -1.90% below its all-time high of $740.73 million, reached on June 30, 2024.
Performance
RARE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RARE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.6% | -55.7% | +1123.0% |
| 3 y3 years | -35.3% | +48.0% | +39.1% |
| 5 y5 years | +15.2% | +1136.1% | +7.0% |
RARE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.6% | +227.4% | -97.7% | +1647.7% | -1.9% | +1123.0% |
| 5 y | 5-year | -42.9% | +227.4% | -97.7% | +1647.7% | -1.9% | +1123.0% |
| alltime | all time | -42.9% | >+9999.0% | -97.7% | +1647.7% | -1.9% | >+9999.0% |
Ultragenyx Pharmaceutical Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $11.17 M(-97.1%) | $726.66 M(-1.9%) |
| Jun 2024 | - | $384.94 M(<-9900.0%) | $740.73 M(+90.5%) |
| Mar 2024 | - | -$58.00 K(-100.0%) | $388.81 M(+0.2%) |
| Dec 2023 | $388.14 M(-22.6%) | $330.61 M(+1210.2%) | $388.14 M(+553.3%) |
| Sep 2023 | - | $25.23 M(-23.6%) | $59.41 M(-88.7%) |
| Jun 2023 | - | $33.02 M(-4673.4%) | $526.06 M(+5.4%) |
| Mar 2023 | - | -$722.00 K(-138.4%) | $498.87 M(-0.5%) |
| Dec 2022 | $501.21 M(+322.8%) | $1.88 M(-99.6%) | $501.21 M(-14.3%) |
| Sep 2022 | - | $491.88 M(+8326.9%) | $585.05 M(+480.8%) |
| Jun 2022 | - | $5.84 M(+262.1%) | $100.72 M(-6.3%) |
| Mar 2022 | - | $1.61 M(-98.1%) | $107.52 M(-9.3%) |
| Dec 2021 | $118.55 M(-80.3%) | $85.72 M(+1035.4%) | $118.55 M(-77.3%) |
| Sep 2021 | - | $7.55 M(-40.2%) | $522.54 M(-2.2%) |
| Jun 2021 | - | $12.63 M(-0.2%) | $534.12 M(-4.2%) |
| Mar 2021 | - | $12.65 M(-97.4%) | $557.31 M(-7.2%) |
| Dec 2020 | $600.27 M(-11.6%) | $489.71 M(+2459.2%) | $600.27 M(+40.9%) |
| Sep 2020 | - | $19.14 M(-46.6%) | $426.00 M(+4.5%) |
| Jun 2020 | - | $35.81 M(-35.6%) | $407.77 M(+6.9%) |
| Mar 2020 | - | $55.62 M(-82.4%) | $381.30 M(-43.9%) |
| Dec 2019 | $679.31 M(+101.7%) | $315.44 M(>+9900.0%) | $679.31 M(+80.6%) |
| Sep 2019 | - | $904.00 K(-90.3%) | $376.11 M(-6.0%) |
| Jun 2019 | - | $9.34 M(-97.4%) | $400.23 M(-0.9%) |
| Mar 2019 | - | $353.62 M(+2788.6%) | $404.05 M(+19.9%) |
| Dec 2018 | $336.85 M | $12.24 M(-51.1%) | $336.85 M(-13.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $25.02 M(+90.0%) | $389.05 M(+6.5%) |
| Jun 2018 | - | $13.17 M(-95.4%) | $365.36 M(+3.3%) |
| Mar 2018 | - | $286.42 M(+344.5%) | $353.72 M(+159.6%) |
| Dec 2017 | $136.27 M(-1.7%) | $64.44 M(+4734.1%) | $136.27 M(-7.2%) |
| Sep 2017 | - | $1.33 M(-12.6%) | $146.77 M(-29.7%) |
| Jun 2017 | - | $1.53 M(-97.8%) | $208.88 M(+0.7%) |
| Mar 2017 | - | $68.97 M(-8.0%) | $207.33 M(+49.5%) |
| Dec 2016 | $138.68 M(-70.3%) | $74.94 M(+18.1%) | $138.68 M(+114.6%) |
| Sep 2016 | - | $63.45 M(<-9900.0%) | $64.62 M(-77.7%) |
| Jun 2016 | - | -$25.00 K(-108.0%) | $289.83 M(-0.9%) |
| Mar 2016 | - | $314.00 K(-64.6%) | $292.45 M(-37.5%) |
| Dec 2015 | $467.57 M(+152.8%) | $887.00 K(-99.7%) | $467.57 M(+0.1%) |
| Sep 2015 | - | $288.65 M(>+9900.0%) | $467.10 M(+95.5%) |
| Jun 2015 | - | $2.60 M(-98.5%) | $238.96 M(+1.1%) |
| Mar 2015 | - | $175.44 M(>+9900.0%) | $236.37 M(+27.8%) |
| Dec 2014 | $184.97 M(>+9900.0%) | $412.00 K(-99.3%) | $184.97 M(+0.2%) |
| Sep 2014 | - | $60.51 M(>+9900.0%) | $184.60 M(+48.7%) |
| Jun 2014 | - | $10.00 K(-100.0%) | $124.16 M(-0.0%) |
| Mar 2014 | - | $124.04 M(>+9900.0%) | $124.21 M(>+9900.0%) |
| Dec 2013 | $171.00 K(-99.8%) | $38.00 K(-50.0%) | $171.00 K(+28.6%) |
| Sep 2013 | - | $76.00 K(+35.7%) | $133.00 K(+133.3%) |
| Jun 2013 | - | $56.00 K(+5500.0%) | $57.00 K(+5600.0%) |
| Mar 2013 | - | $1000.00 | $1000.00 |
| Dec 2012 | $89.24 M(+415.0%) | - | - |
| Dec 2011 | $17.33 M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual cash flow from financing activities?
- What is the all time high annual CFF for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual CFF year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly CFF year-on-year change?
- What is Ultragenyx Pharmaceutical TTM cash flow from financing activities?
- What is the all time high TTM CFF for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM CFF year-on-year change?
What is Ultragenyx Pharmaceutical annual cash flow from financing activities?
The current annual CFF of RARE is $388.14 M
What is the all time high annual CFF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual cash flow from financing activities is $679.31 M
What is Ultragenyx Pharmaceutical annual CFF year-on-year change?
Over the past year, RARE annual cash flow from financing activities has changed by -$113.07 M (-22.56%)
What is Ultragenyx Pharmaceutical quarterly cash flow from financing activities?
The current quarterly CFF of RARE is $11.17 M
What is the all time high quarterly CFF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly cash flow from financing activities is $491.88 M
What is Ultragenyx Pharmaceutical quarterly CFF year-on-year change?
Over the past year, RARE quarterly cash flow from financing activities has changed by -$14.06 M (-55.72%)
What is Ultragenyx Pharmaceutical TTM cash flow from financing activities?
The current TTM CFF of RARE is $726.66 M
What is the all time high TTM CFF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM cash flow from financing activities is $740.73 M
What is Ultragenyx Pharmaceutical TTM CFF year-on-year change?
Over the past year, RARE TTM cash flow from financing activities has changed by +$667.25 M (+1123.05%)